Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:
Chia-Chun Chiang, MD
Headache Fellow
Mayo Clinic Arizona
Scottsdale, Arizona
The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
